Back

Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES

26 August 2023 (16:15 - 16:50)
Organised by: Logo
Congress Presentation Part of: Biomarkers for risk stratification in acute coronary syndromes (2) Biomarkers ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

6 More presentations in this session

Presentation thumbnail
Assay of macrotroponin I not complexed with troponin T: effect on the performance of troponin T to predict myocardial infarction
Professor C. Pemberton (Christchurch, NZ)
Abstract Slides Video
Presentation thumbnail
The role of arginine vasopressin in the pathophysiology of microvascular dysfunction after ST-elevation myocardial infarction
Doctor A. Alatta (Newcastle-Upon-Tyne, GB)
Abstract Slides Video
Presentation thumbnail
Does a high baseline high sensitivity cardiac troponin T allow for the early diagnosis of acute myocardial infarction?
Doctor J. Knott (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Interleukin-6 plasma levels are elevated in patients with acute myocardial infarction and predict death or recurrent infarction within 1 year - a case-control study
Mr M. Matter (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Nourin miRNAs: novel biomarkers highly expressed in unstable angina patients with normal ECG and negative hs-troponin and dropped post percutaneous coronary intervention
Professor H. Kandil (Cairo, EG)
Abstract Slides Video

Access the full session

Session thumbnail
Biomarkers for risk stratification in acute coronary syndromes (2)

The Event

Event poster

ESC Congress 2023

26 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Lipoprotein (a) and lipidemic parameters in PCSK-9 inhibitor patients. Experience from a specialized centre in Greece.
thumbnail
Congress Presentation
Impact of elevated lipoprotein(a) on LDL-C lowering efficacy in ACS patients undergoing triple lipid-lowering therapy: insights from LAI-REACT-LP(a) sub-study
thumbnail
Congress Presentation
Prognostic values of lipoprotein(a) levels for secondary prevention of acute coronary syndrome among patients who underwent primary percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources